Neuroscience

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

Dec 9, 2024

Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors New York, NY, December 9, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz,...

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

Dec 3, 2024

Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical...

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

EDEN PRAIRIE, Minn., October 24, 2024 - PRISM MediaWire - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Oct 15, 2024

KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...

NEWSROOM

Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board

Former Merck USA President Joins Klotho Neurosciences’ Board of Directors

NeuroOne® Medical Technologies to Present at the 2024 ThinkEquity Conference

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Contact Us